At AACR IO 2026, Nobel laureate Fred Ramsdell explained the research history of regulatory T cells (Tregs) and the...
A string of innovative clinical trials designed to accelerate the pace at which personalized cancer medicines are developed have...
Guest Post by Peter A. Jones, PhD, DSc Research Director and Chief Scientific Officer Van Andel Research Institute
The rapid fire of U.S. Food and Drug Administration (FDA) approvals of new treatments for cancer continued last week...
When the hottest minds in cancer genomics meet the hottest minds in computational and systems biology, you can rest...
Last week, the U.S. Food and Drug Administration (FDA) announced the first-ever approval of a treatment for Waldenström macroglobulinemia,...
Wednesday is World Cancer Day. This international initiative of the Union for International Cancer Control (UICC) takes place every...
A recent study in the AACR’s journal Cancer Epidemiology, Biomarkers & Prevention suggests that different types of cancer fear...
Big progress was made in 2014, in the form of FDA approvals for new immunotherapies, targeted therapies, and a...
Hugh Gannon, PhD, a recipient of the 2013 Anna D. Barker Fellowship in Basic Cancer Research, is studying p53's...
With the late-breaking and clinical trial-placeholder abstract deadlines a week away, we thought it was a good time to...